Insmed Q4 revenue $56.1M (+36% YoY), net loss $113M; guides 30%+ ARIKAYCE growth in 2022

INSMED Inc

2021-FY EPS reported -$3.88 revenue$188,461,000

Full-year 2021 revenue $188.5M (vs $164.4M); ARIKAYCE sales $159.5M US, $16.0M Japan, $12.9M Europe/ROW.
Net loss for 2021 $434.7M ($3.88/share) vs $294.1M ($3.01/share); Q4 net loss $113.0M ($0.95/share).
Cash and marketable securities $766.8M; company expects cash runway into 2024.
Brensocatib Phase 3 ASPEN (bronchiectasis) 50% enrolled; topline data expected early 2023.
Director Steinar J. Engelsen not standing for re-election at 2022 Annual Meeting; no disagreement.

item 2.02 item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Steinar J. Engelsen

Director

INSM · INSMED Inc

Filed: February 17, 2022, 6:59 PM ET

On February 15, 2022, Steinar J. Engelsen, M.D. notified the board of directors (the “Board”) of the Company that he will not stand for re-election to the Board upon the expiration of his current term as a Class I director, which occurs at the Company’s 2022 Annual Meeting of Shareholders (the “Annual Meeting”).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Steinar J. Engelsen departed as Director at INSMED Inc.

Action: not stand for re-election
Role: Director

Exact text from the filing

On February 15, 2022, Steinar J. Engelsen, M.D. notified the board of directors (the “Board”) of the Company that he will not stand for re-election to the Board upon the expiration of his current term as a Class I director, which occurs at the Company’s 2022 Annual Meeting of Shareholders (the “Annual Meeting”).

View on SEC.gov

INSMED Inc filing history →

Source: SEC EDGAR

accession 0001140361-22-005849

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.